Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

30 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Analysis of conformational determinants underlying HSP90-kinase interaction.
Kancha RK, Bartosch N, Duyster J. Kancha RK, et al. PLoS One. 2013 Jul 2;8(7):e68394. doi: 10.1371/journal.pone.0068394. Print 2013. PLoS One. 2013. PMID: 23844194 Free PMC article.
Computational analysis of ABL kinase mutations allows predicting drug sensitivity against selective kinase inhibitors.
Kamasani S, Akula S, Sivan SK, Manga V, Duyster J, Vudem DR, Kancha RK. Kamasani S, et al. Among authors: kancha rk. Tumour Biol. 2017 May;39(5):1010428317701643. doi: 10.1177/1010428317701643. Tumour Biol. 2017. PMID: 28475010
Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.
Kancha RK, von Bubnoff N, Bartosch N, Peschel C, Engh RA, Duyster J. Kancha RK, et al. PLoS One. 2011;6(10):e26760. doi: 10.1371/journal.pone.0026760. Epub 2011 Oct 28. PLoS One. 2011. PMID: 22046346 Free PMC article.
The epidermal growth factor receptor-L861Q mutation increases kinase activity without leading to enhanced sensitivity toward epidermal growth factor receptor kinase inhibitors.
Kancha RK, Peschel C, Duyster J. Kancha RK, et al. J Thorac Oncol. 2011 Feb;6(2):387-92. doi: 10.1097/JTO.0b013e3182021f3e. J Thorac Oncol. 2011. PMID: 21252719
Imatinib and leptomycin B are effective in overcoming imatinib-resistance due to Bcr-Abl amplification and clonal evolution but not due to Bcr-Abl kinase domain mutation.
Kancha RK, von Bubnoff N, Miething C, Peschel C, Götze KS, Duyster J. Kancha RK, et al. Haematologica. 2008 Nov;93(11):1718-22. doi: 10.3324/haematol.13207. Epub 2008 Aug 25. Haematologica. 2008. PMID: 18728023
Bis(1H-indol-2-yl)methanones are effective inhibitors of FLT3-ITD tyrosine kinase and partially overcome resistance to PKC412A in vitro.
Heidel F, Lipka DB, Mirea FK, Mahboobi S, Grundler R, Kancha RK, Duyster J, Naumann M, Huber C, Böhmer FD, Fischer T. Heidel F, et al. Among authors: kancha rk. Br J Haematol. 2009 Mar;144(6):865-74. doi: 10.1111/j.1365-2141.2008.07567.x. Epub 2009 Jan 16. Br J Haematol. 2009. PMID: 19183186
Elucidation of conformational diversity of druggable enzymes and classification of chemical modulators based on inhibitor-bound structures.
Akula S, Vanamamalai VK, Nair Ru VP, Vudem DR, Kancha RK. Akula S, et al. Among authors: kancha rk. J Biomol Struct Dyn. 2019 Oct;37(17):4563-4568. doi: 10.1080/07391102.2018.1553740. Epub 2019 Jan 9. J Biomol Struct Dyn. 2019. PMID: 30488775
30 results
Jump to page
Feedback